Savara has multiple products in various stages of clinical development.

  • A Phase 3 clinical trial of Molgradex to treat patients with PAP is currently ongoing worldwide; top-line results are anticipated in the fourth quarter 2018.
  • Savara anticipates initiating a pivotal Phase 3 clinical trial of AeroVanc for the treatment of MRSA in cystic fibrosis patients in Q3 of 2017.
  • Aironite is currently in clinical studies for the treatment of heart failure with preserved ejection fraction (HFpEF).

This page contains Forward Looking Statements, please see Terms of Use

Go to products

Back to Top